Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Medikamentöse Therapie bei Erwachsenen mit angeborenen Herzfehlern (EMAH)

Margarita Brida und Gerhard-Paul Diller

 

  1. Webb G, Mulder BJ, Aboulhosn J, et al. The care of adults with congenital heart disease across the globe: Current assessment and future perspective: A position statement from the International Society for Adult Congenital Heart Disease (ISACHD). International journal of cardiology 2015; 195:326--33.
  2. van der Bom T, Bouma BJ, Meijboom FJ, et al. The prevalence of adult congenital heart disease, results from a systematic review and evidence based calculation. American heart journal 2012; 164:568--75.
  3. Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). European heart journal 2010; 31:2915--57.
  4. Verheugt CL, Uiterwaal CS, Grobbee DE, et al. Long-term prognosis of congenital heart defects: a systematic review. International journal of cardiology 2008; 131:25--32.
  5. Tutarel O, Kempny A, Alonso-Gonzalez R, et al. Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. European heart journal 2014; 35:725--32.
  6. Engelings CC, Helm PC, Abdul-Khaliq H, et al. Cause of death in adults with congenital heart disease - An analysis of the German National Register for Congenital Heart Defects. International journal of cardiology 2016; 211:31--6.
  7. Verheugt CL, Uiterwaal CS, van der Velde ET, et al. Mortality in adult congenital heart disease. European heart journal 2010; 31:1220--9.
  8. Budts W, Roos-Hesselink J, Radle-Hurst T, et al. Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology. European heart journal 2016; 37:1419--27.
  9. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European heart journal 2016.
  10. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. European heart journal 2015; 36:1831--8.
  11. Bavishi C, Khan AR, Ather S. Digoxin in patients with atrial fibrillation and heart failure: A meta-analysis. International journal of cardiology 2015; 188:99--101.
  12. Ziff OJ, Kotecha D. Digoxin: The good and the bad. Trends in cardiovascular medicine 2016.
  13. Therrien J, Provost Y, Harrison J, et al. Effect of angiotensin receptor blockade on systemic right ventricular function and size: a small, randomized, placebo-controlled study. International journal of cardiology 2008; 129:187--92.
  14. van der Bom T, Winter MM, Bouma BJ, et al. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. Circulation 2013; 127:322--30.
  15. Shabanian R, Shahbaznejad L, Razaghian A, et al. Sildenafil and ventriculo-arterial coupling in Fontan-palliated patients: a noninvasive echocardiographic assessment. Pediatric cardiology 2013; 34:129--34.
  16. Kouatli AA, Garcia JA, Zellers TM, et al. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 1997; 96:1507--12.
  17. Walsh EP, Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation 2007; 115:534--45.
  18. Oechslin EN, Harrison DA, Connelly MS, et al. Mode of death in adults with congenital heart disease. The American journal of cardiology 2000; 86:1111--6.
  19. Kaemmerer H, Bauer U, Pensl U, et al. Management of emergencies in adults with congenital cardiac disease. The American journal of cardiology 2008; 101:521--5.
  20. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Heart rhythm : the official journal of the Heart Rhythm Society 2014; 11:e102--65.
  21. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. Journal of the American College of Cardiology 1996; 28:1458--63.
  22. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Journal of the American College of Cardiology 1992; 20:527--32.
  23. Lane DA, Lip GYH. Use of the CHA2DS2-VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. Circulation 2012; 126:860--5.
  24. Pujol C, Niesert AC, Engelhardt A, et al. Usefulness of Direct Oral Anticoagulants in Adult Congenital Heart Disease. The American journal of cardiology 2016; 117:450--5.
  25. Hoffmann A, Chockalingam P, Balint OH, et al. Cerebrovascular accidents in adult patients with congenital heart disease. Heart (British Cardiac Society) 2010; 96:1223--6.
  26. DeSimone CV, Friedman PA, Noheria A, et al. Stroke or transient ischemic attack in patients with transvenous pacemaker or defibrillator and echocardiographically detected patent foramen ovale. Circulation 2013; 128:1433--41.
  27. Giannakoulas G, Boutsikou M. The Gordian knot of thromboembolism in congenital heart disease. Heart (British Cardiac Society) 2015; 101:1523--4.
  28. Khairy P. Thrombosis in congenital heart disease. Expert review of cardiovascular therapy 2013; 11:1579--82.
  29. Bouchardy J, Therrien J, Pilote L, et al. Atrial arrhythmias in adults with congenital heart disease. Circulation 2009; 120:1679--86.
  30. Khairy P, Fernandes SM, Mayer JE, Jr., et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 2008; 117:85--92.
  31. Monagle P, Cochrane A, Roberts R, et al. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. Journal of the American College of Cardiology 2011; 58:645--51.
  32. Potter BJ, Leong-Sit P, Fernandes SM, et al. Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation. International journal of cardiology 2013; 168:3940--3.
  33. Engelfriet PM, Duffels MG, Moller T, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart (British Cardiac Society) 2007; 93:682--7.
  34. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European heart journal 2016; 37:67--119.
  35. Radke RM, Diller GP, Baumgartner H. The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease. Expert review of cardiovascular therapy 2013;11:919-31.
  36. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007; 115:1039--50.
  37. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129:57--65.
  38. D'Alto M, Diller GP. Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. Heart (British Cardiac Society) 2014; 100:1322--8.
  39. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114:48--54.
  40. Diller GP, Alonso-Gonzalez R, Dimopoulos K, et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. International journal of cardiology 2013; 167:840--7.
  41. Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. International journal of cardiology 2013; 164:64--9.
  42. Rosenkranz S, Ghofrani HA, Beghetti M, et al. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart (British Cardiac Society) 2015; 101:1792--9.
  43. Lammers AE, Diller GP. Riociguat for pulmonary hypertension in congenital heart disease: opportunities and challenges. Heart (British Cardiac Society) 2015; 101:1771--2.
  44. Channick RN, Delcroix M, Ghofrani HA, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart failure 2015; 3:1--8.
  45. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. The New England journal of medicine 2013; 369:809--18.
  46. D'Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. International journal of cardiology 2012; 155:378--82.
  47. Jacobs W, Boonstra A, Marcus JT, et al. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2009; 28:280--4.
  48. Sitbon O, Channick R, Chin KM, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. The New England journal of medicine 2015; 373:2522--33.
  49. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). European heart journal 2015; 36:3075--128.
  50. Niwa K, Nakazawa M, Tateno S, et al. Infective endocarditis in congenital heart disease: Japanese national collaboration study. Heart (British Cardiac Society) 2005; 91:795--800.
  51. Moller JH, Anderson RC. 1,000 consecutive children with a cardiac malformation with 26- to 37-year follow-up. The American journal of cardiology 1992; 70:661--7.
  52. Mulder BJ. Endocarditis in congenital heart disease: who is at highest risk? Circulation 2013; 128:1396--7.

 

 

Belastungen bei Erwachsenen mit angeborenen Herzfehlern (EMAH): Sport, Beruf, Familienplanung und Schwangerschaft

Nicole NAGDYMAN, Michael HUNTGEBURTH, Alfred HAGER, Rhoia NEIDENBACH1 und Harald KAEMMERER1

 

  1. Kaemmerer H, Hess J. [Adult patients with congenital heart abnormalities: present and future]. Dtsch Med Wochenschr 2005;130:97-101.
  2. Schmaltz AA, Bauer UM. [Adults with congenital heart disease: treatment and medical problems]. Herz 2013;38:639-51; quiz 52-4.
  3. Stark J. Do we really correct congenital heart defects? J Thorac Cardiovasc Surg 1989;97:1-9.
  4. Kaemmerer H, Lummert E, Engelhardt A, Ewert P. Angeborene Herzfehler: Zur Nachsorge ermuntern. Der Hausarzt 2014;17:38-41.
  5. Budts W, Borjesson M, Chessa M, et al. Physical activity in adolescents and adults with congenital heart defects: individualized exercise prescription. Eur Heart J 2013;34:3669-74.
  6. Dean PN, Gillespie CW, Greene EA, et al. Sports participation and quality of life in adolescents and young adults with congenital heart disease. Congenit Heart Dis 2015;10:169-79.
  7. Kempny A, Dimopoulos K, Uebing A, et al. Reference values for exercise limitations among adults with congenital heart disease. Relation to activities of daily life--single centre experience and review of published data. Eur Heart J 2012;33:1386-96.
  8. Opic P, Utens EM, Cuypers JA, et al. Sports participation in adults with congenital heart disease. Int J Cardiol 2015;187:175-82.
  9. Takken T, Giardini A, Reybrouck T, et al. Recommendations for physical activity, recreation sport, and exercise training in paediatric patients with congenital heart disease: a report from the Exercise, Basic & Translational Research Section of the European Association of Cardiovascular Prevention and Rehabilitation, the European Congenital Heart and Lung Exercise Group, and the Association for European Paediatric Cardiology. Eur J Prev Cardiol 2012;19:1034-65.
  10. Bhatt AB, Foster E, Kuehl K, et al. Congenital heart disease in the older adult: a scientific statement from the American Heart Association. Circulation 2015;131:1884-931.
  11. Lummert E., Hauser M., Vigl M., et al. Noncardiac comorbidities of congenital heart disease in adults.  Am J Cardiol; 2014. p. S 109.
  12. Chaix MA, Marcotte F, Dore A, et al. Risks and Benefits of Exercise Training in Adults With Congenital Heart Disease. Can J Cardiol 2016;32:459-66.
  13. Kaemmerer H, Tintner H, Konig U, Fritsch J, Sechtem U, Hopp HW. [Psychosocial problems of adolescents and adults with congenital heart defects]. Z Kardiol 1994;83:194-200.
  14. Ladouceur M, Iserin L, Cohen S, Legendre A, Boudjemline Y, Bonnet D. Key issues of daily life in adults with congenital heart disease. Arch Cardiovasc Dis 2013;106:404-12.
  15. Klein HH, Krämer A, Pieske BM, Trappe HJ, H. dV. Positionspapier Fahreignung bei kardiovaskulären Erkrankungen. Der Kardiologe 2010;4:441-173.
  16. Grabitz RG, Kaemmerer H, Mohr FW. [Adult patients with congenital heart disease]. Internist (Berl) 2013;54:18, 20-7.
  17. Perloff JK. Pregnancy in congenital heart disease: the mother and the fetus. In: Perloff JK, JS C, eds. Congenital heart disease in adults. Philadelphia: WB Saunders; 2009:194-220.
  18. Connolly HM. Pregnancy in women with congenital heart disease. Curr Cardiol Rep 2005;7:305-9.
  19. Kaemmerer H, Schneider KTM, V. S-K. Schwangerschaft bei angeborenen Herzfehlern. In: Schumacher G, Hess J, Bühlmeyer K, eds. Klinische Kinderkardiologie. Heidelberg: Springer 2008:601-8.
  20. Kafka H, Johnson MR, Gatzoulis MA. The team approach to pregnancy and congenital heart disease. Cardiol Clin 2006;24:587-605, vi.
  21. Karamermer Y, Roos-Hesselink JW. Pregnancy and adult congenital heart disease. Expert Rev Cardiovasc Ther 2007;5:859-69.
  22. European Society of G, Association for European Paediatric C, German Society for Gender M, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011;32:3147-97.
  23. Tobler D, Fernandes SM, Wald RM, et al. Pregnancy outcomes in women with transposition of the great arteries and arterial switch operation. Am J Cardiol 2010;106:417-20.
  24. Trigas V, Nagdyman N, Pildner von Steinburg S, et al. Pregnancy-related obstetric and cardiologic problems in women after atrial switch operation for transposition of the great arteries. Circ J 2014;78:443-9.
  25. Uebing A, Gatzoulis MA, von Kaisenberg C, Kramer HH, Strauss A. Congenital heart disease in pregnancy. Dtsch Arztebl Int 2008;105:347-54.
  26. Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010;31:2124-32.
  27. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001;104:515-21.

 

 

Rhythmusstörungen: Medikamentöse und interventionelle Therapie, implantierbare Geräte

Rhythmusstörungen: Medikamentöse und interventionelle Therapie, implantierbare Kristina Wasmer und Lars Eckardt

 

  1. Khairy P, Van Hare GF, Balaji S, Berul CI, Cecchin F, Cohen MI et al. PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Heart Rhythm. 2014; 1:e102-65.
  2. Jensen S, Idorn L, Norager B, Vejlstrup N, Sondergaard L. Anticoagulation in adults with congenital heart disease: the who, the when and the how? Heart 2015; 101:424-9.
  3. Heidendael J, Bokma J, de Groot J, Koolbergen DR, Mulder BJ, Bouma BJ. Weighing the risks: thrombotic and bleeding events in adults with atrial arrhythmias and congenital heart disease. Int J Cardiol 2015; 186:315-20.
  4. Pujok C, Niesert AC, Engelhardt A, Schoen P, Kusmenkov E, Pittrow D et al. Usefulness of direct oral anticoagulants in adult congenital heart disease. Am J Cardiol 2016; 117:450-55.
  5. Khairy P, Fernandes SM, Mayer JE Jr, Triedman JK, Walsh EP, Lock JE et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 2008; 117:85-92.
  6. Khairy P, Harris L, Landzberg MJ, Fernandes SM, Barlow A, Mercier LA et al. Sudden death and defibrillators in transposition of the great arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm Electrophysiol 2008; 1:250-7.
  7. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J 2013; 34:1481-8.
  8. Koyak Z, Kroon B, de Groot JR, Wagenaar LJ, van Dijk AP, Mulder BA et al. Efficacy of antiarrhythmic drugs in adults with congenital heart disease and supraventricular tachycardias. Am J Cardiol 2013; 112:1461-7.
  9. Miyazaki A, Ohuchi H, Kurosaki K, Kamakura S, Yagihara T, Yamada O. Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease. Circ J 2008; 72:1998-2003.
  10. Zeppenfeld K, Schalij MJ, Bartelings MM, Tedrow UB, Koplan BA, Soejima K, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. Circulation. 2007; 116:2241-52.
  11. Kapel GF, Reichlin T, Wijnmaalen AP, Piers SR, Holman ER, Tedrow UB, et al. Re-entry using anatomically determined isthmuses: a curable ventricular tachycardia in repaired congenital heart disease. Circ Arrhythm Electrophysiol. 2015; 8:102-9.
  12. van Zyl M, Kapa S, Padmanabhan D, Chen FC, Mulpuru SK, Packer DL, et al. Mechanism and outcomes of catheter ablation for ventricular tachycardia in adults with repaired congenital heart disease. Heart Rhythm. 2016 13:1449-54.
  13. Khairy P, Harris L, Landzberg MJ, Viswanathan S, Barlow A, Gatzoulis MA, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation. 2008; 117:363-70.
  14. Verheugt CL, Uiterwaal CS, van der Velde ET, Meijboom FJ, Pieper PG, van Dijk AP, et al. Mortality in adult congenital heart disease. Eur Heart J. 2010; 31:1220-9.
  15. Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol. 1998; 32:245-51.
  16. Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ, et al. Sudden cardiac death in adult congenital heart disease. Circulation 2012; 126:1944-54.
  17. Walsh EP. Sudden death in adult congenital heart disease: risk stratification in 2014. Heart Rhythm. 2014; 11:1735-42.
  18. Gallego P, Gonzalez AE, Sanchez-Recalde A, Peinado R, Polo L, Gomez-Rubin C, et al. Incidence and predictors of sudden cardiac arrest in adults with congenital heart defects repaired before adult life. Am J Cardiol. 2012; 110:109-17.
  19. Hayward RM, Dewland TA, Moyers B, Vittinghoff E, Tanel RE, Marcus GM, et al. Device complications in adult congenital heart disease. Heart Rhythm. 2015; 12:338-44.
  20. Frommeyer G, Dechering DG, Zumhagen S, Löher A, Köbe J, Eckardt L, Reinke F. Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience. Clin Res Cardiol. 2016; 105:89-93.
  21. Kalra Y, Radbill AE, Johns JA, Fish FA, Kannankeril PJ. Antitachycardia pacing reduces appropriate and inappropriate shocks in children and congenital heart disease patients. Heart Rhythm. 2012; 9:1829-34.
  22. Cecchin F, Frangini PA, Brown DW, Fynn-Thompson F, Alexander ME, Triedman JK, et al. Cardiac resynchronization therapy (and multisite pacing) in pediatrics and congenital heart disease: five years experience in a single institution. J Cardiovasc Electrophysiol. 2009; 20:58-65.
  23. Dubin AM, Janousek J, Rhee E, Strieper MJ, Cecchin F, Law IH, et al. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol. 2005; 46:2277-83.
  24. Janousek J, Gebauer RA, Abdul-Khaliq H, Turner M, Kornyei L, Grollmuss O, et al.; Working Group for Cardiac Dysrhythmias and Electrophysiology of the Association for European Paediatric Cardiology. Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. Heart. 2009; 95:1165-71.
  25. Krieger EV, Valente AM. Heart failure treatment in adults with congenital heart disease: where do we stand in 2014? Heart. 2014; 100:1329-34.

 

 

Langzeitprobleme nach früheren Eingriffen: Re-Interventionen nach Eingriffen im rechtsventrikulären Ausflusstrakt – Diagnostik und Therapie

Andreas Eicken, Peter Ewert, Harald Kaemmerer

bei allen Stellen fehlt die Angabe des Bandes (volumes).

 

  1. Kan JS WR, Mitchell SE, Gardner TJ. Percutaneous balloon valvuloplasty: a new method for treating congenital pulmonary valve stenosis. New England Journal of Medicine. 1982;307,540-542.
  2. Bailliard F AR. Tetralogy of Fallot. Orphanet J Rare Dis. 2009;Volume 4:page 2.
  3. Woldu KL BA, Bacha EA, Wiliiams IS. Impact of neonatal versus nonneonatal total repair of Tetralogy of Fallot on Growth in the first year of life. Ann Thorac Surg. 2014;98,1399-1404.
  4. Cuypers JA MM, Konings EE, Opi? P, Utens EM, Helbing WA, Witsenburg M, van den Bosch AE, Ouhlous M, van Domburg RT, Rizopoulos D, Meijboom FJ, Boersma E, Bogers AJ, Roos-Hesselink JW. Unnatural history of tetralogy of Fallot: prospective follow-up of 40 years after surgical correction. Circulation. 2014;130(22),1944-1953.
  5. Baumgartner H BP, De Groot NM, de Haan F, Deanfield JE, Galie N et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31,2915-2957.
  6. Wessel HU PM. Exercise studies in tetralogy of Fallot: a review. Pediatric Cardiology. 1999;20(1),39-47.
  7. Diller GP DK, Okonko D, Li W, Babu-Narayan SV, Broberg CS, Johansson B, Bouzas B, Mullen MJ, Poole-Wilson PA, Francis DP, Gatzoulis MA. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. . Circulation. 2005;112,828-835.
  8. Shimazaki Y BE, Kirklin JW. The natural history of isolated congenital pulmonary valve incompetence: Surgical implications. Thorac cardiovasc surgeon. 1984;32,257-259.
  9. Gatzoulis MA TJ, Somerville J, Redington AN. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;92(2),231-237.
  10. Gatzoulis MA BS, Webber SA, Siu SC, Hokanson JS, Poile C, Rosenthal M, Nakazawa M, Moller JH, Gillette PC, Webb GD, Redington AN. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356(234),975-981.
  11. Ferraz Cavalcanti PE SM, Santos CA, Esmeraldo IM, de Escobar RR, de Menezes AM, de Azevedo OM Jr, de Vasconcelos Silva FP, Lins RF, Lima Rde C. Pulmonary valve replacement after operative repair of tetralogy of Fallot: meta-analysis and meta-regression of 3,118 patients from 48 studies. JACC. 2013;62(23),2227-2243.
  12. Harrild DM BC, Cecchin F, Geva T, Gauvreau K, Pigula F, Walsh EP. Pulmonary valve replacement in tetralogy of Fallot: impact on survival and ventricular tachycardia. Circulation. 2009;119(3),445-451.
  13. Homann M HJ, Mendler N, Paek SU, Holper K, Meisner H, Lange R. . Reconstruction of the RVOT with valved biological conduits: 25 years experience with allografts and xenografts. . Eur J Cardiothorac Surg 2000;17,624-630.
  14. Khambadkone S, Coats L, Taylor A, Boudjemline Y, Derrick G, Tsang V, Cooper J, Muthurangu V, Hegde SR, Razavi RS, Pellerin D, Deanfield J, Bonhoeffer P. Percutaneous pulmonary valve implantation in humans: results in 59 consecutive patients. Circulation. 2005;112,1189-1197.
  15. Haas F SC, Hörer J, Kostolny M, Holper K, Lange R. Is there a role for mechanical valved conduits in the pulmonary position? Ann Thorac Surg. 2005;79(5),1662-7, discussion 1667-1668.
  16. Freling HG, van Slooten YJ, van Melle JP, Ebels T, Hoendermis ES, Berger RM, Hillege HL, Waterbolk TW, van Veldhuisen DJ, Willems TP, Pieper PG. Pulmonary valve replacement: twenty-six years of experience with mechanical valvar prostheses. Ann Thorac Surg. 2015;99(3),905-910.
  17. Dehaki MG GA, Omrani G, Javadikasgari H. Long-Term Outcome of Mechanical Pulmonary Valve Replacement in 121 Patients with Congenital Heart Disease. Thorac Cardiovasc Surg. 2015;63(5),367-372.
  18. Therrien J SS, McLaughlin PR, Liu PP, Williams WG, Webb GD. Pulmonary valve replacement in adults late after repair of tetralogy of fallot: are we operating too late? JACC. 2000;1670-1675.
  19. Therrien J PY, Merchant N, Williams W, Colman J, Webb G. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol. 2005;36(5)779-782.
  20. Buechel ER DH, Kellenberger CJ, Dodge-Khatami A, Pretre R, Berger F, Bauersfeld U. Remodelling of the right ventricle after early pulmonary valve replacement in children with repaired tetralogy of Fallot: assessment by cardiovascular magnetic resonance. Eur Heart J 2005;26(24),2721-2727.
  21. Oosterhof T vSA, Vliegen HW, Meijboom FJ, van Dijk AP, Spijkerboer AM, Bouma BJ, Zwinderman AH, Hazekamp MG, de Roos A, Mulder BJ. Preoperative thresholds for pulmonary valve replacement in patients with corrected tetralogy of Fallot using cardiovascular magnetic resonance. Circulation. 2007;116(5),545-551.
  22. Frigiola A, Tsang V, Bull C, Coats L, Khambadkone S, Derrick G, Mist B, Walker F, van Doorn C, Bonhoeffer P, Taylor AM. Biventricular response after pulmonary valve replacement for right ventricular outflow tract dysfunction: is age a predictor of outcome? Circulation. 2008;118,S182-190.
  23. Schuler G PK, Johnson AD, Francis G, Ashburn W, Dennish G, Daily PO, Ross J Jr. Serial noninvasive assessment of left ventricular hypertrophy and function after surgical correction of aortic regurgitation. Am J Cardiol. 1979;44(4),585-594.
  24. Bonhoeffer P, Boudjemline Y, Saliba Z, Merckx J, Aggoun Y, Bonnet D, Acar P, Le Bidois J, Sidi D, Kachaner J. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet. 2000;356,1403-1405.
  25. Butera G, Milanesi O, Spadoni I, Piazza L, Donti A, Ricci C, Agnoletti G, Pangrazi A, Chessa M, Carminati M. Melody transcatheter pulmonary valve implantation. Results from the registry of the Italian society of pediatric cardiology. Catheter Cardiovasc Interv.2013;81(2), 310-316.
  26. Eicken A, Ewert P, Hager A, Peters B, Fratz S, Kuehne T, Busch R, Hess J, Berger F. Percutaneous pulmonary valve implantation: two-centre experience with more than 100 patients. Eur Heart J. 2011;32,1260-1265.
  27. McElhinney DB HW, Zahn EM, Jones TK, Cheatham JP, Lock JE, Vincent JA. . Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded US Medody trial. . Circulation. 2010;122,507-516.
  28. Haas NA MA, Neudorf U, Mortezaeian H, Abdel-Wahab M, Schneider H, De Wolf D, Petit J, Narayanswami S, Laser KT, Sandica E. Percutaneous implantation of the Edwards SAPIEN(™) pulmonic valve: initial results in the first 22 patients. Clin Res Cardiol. 2013;102(2),119-128.
  29. Momenah TS, El Oakley R, Al Najashi K, Khoshhal S, Al Qethamy H, Bonhoeffer P. Extended application of percutaneous pulmonary valve implantation. J Am Coll Cardiol. 2009;53,1859-1863.
  30. S. Schubert MK, A. Eicken, F. Berger, P. Ewert. Transcatheter implantation of the Edwards SAPIEN XT and Sapien 3 valves: options for treatment of right heart valvular lesions. Clinical Research in Cardiology. submitted 2016.
  31. Schievano S TA, Capelli C, Coats L, Walker F, Lurz P, Nordmeyer J, Wright S, Khambadkone S, Tsang V, Carminati M, Bonhoeffer P. First-in-man implantation of a novel percutaneous valve: a new approach to medical device develpment. Eurintervention. 2010;5(6),745-750.
  32. Promphan W PP, Siripornpitak S, Qureshi SA, Layangool T. Percutaneous pulmonary valve implantation with the Venus P-valve: clinical experience and early results. Cardiology in the Young. 2016;26,698-710.
  33. Boshoff DE CB, Heying R, Troost E, Kefer J, Budts W, Gewillig M. Off-label use of percutaneous pulmonary valved stents in the right ventricular ourflow tract: time to rewrite the label? Catheter Cardiovasc Interv. 2013;81(6),987-995.

 

 

Erstdiagnose im Erwachsenenalter

Oktay Tutarel 

 

  1. Diller GP, Breithardt G, Baumgartner H. Congenital heart defects in adulthood. Dtsch Arztebl Int 2011;108:452-9.
  2. Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010;31:2915-57.
  3. DeFaria Yeh D, King ME. Congenital heart disease in the adult: what should the adult cardiologist know? Curr Cardiol Rep 2015;17:25.
  4. Roifman I, Therrien J, Ionescu-Ittu R, et al. Coarctation of the aorta and coronary artery disease: fact or fiction? Circulation 2012;126:16-21.
  5. Humenberger M, Rosenhek R, Gabriel H, et al. Benefit of atrial septal defect closure in adults: impact of age. Eur Heart J 2011;32:553-60.
  6. Silversides CK, Haberer K, Siu SC, et al. Predictors of atrial arrhythmias after device closure of secundum type atrial septal defects in adults. Am J Cardiol 2008;101:683-7.
  7. Kuijpers JM, van der Bom T, van Riel AC, et al. Secundum atrial septal defect is associated with reduced survival in adult men. Eur Heart J 2015;36:2079-2086.
  8. D'Alto M, Diller GP. Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. Heart 2014;100:1322-8.
  9. van Son JA, Danielson GK, Huhta JC, et al. Late results of systemic atrioventricular valve replacement in corrected transposition. J Thorac Cardiovasc Surg 1995;109:642-52; discussion 652-3.
  10. Krieger EV, Valente AM. Heart failure treatment in adults with congenital heart disease: where do we stand in 2014? Heart 2014;100:1329-34.
  11. John AS, Schaff HV, Drew T, et al. Adult presentation of interrupted aortic arch: case presentation and a review of the medical literature. Congenit Heart Dis 2011;6:269-75.

 

 

 

  1. Besevic J et al: Reproduktive factors and epithelial ovarian cancer survival in the EPIC cohort study Br J Cancer 2015;113(11)1622-31
  2. Wong AS et al: Reappraisial of endometrial thickness for the detection of endometrial cancer in postmenopausal bleeding:a retrospective cohort study BJOG 2016;123:439-46
  3. Jasilionis D et Al: Longevity and education: a demogaphic perspective.Gerontology 62 (2016)3,253-62
  4. Yusuf S, Lonn E, Pais PN et al:  HOPE-3 Investigators. Blood   Pressure and Cholesterol   Lowering in Persons without  Cardiovascular Disease.  N Engl J Med 2016; 374:2032–43.
  5. Wenderlein JM: Gesamtmortalität reduzierbar mit hormoneller Prävention Frauenarzt 57 (2016)9:888-93
  6. Wenderlein J: Östrogene verbessern Lipid-Profil. gyne, 1: 35-40 (2015)